title: Implication of IRF4 aberrant gene expression in the acute leukemias of childhood.
abstract: The most frequent targets of genetic alterations in human leukemias are transcription factor genes with essential functions in normal blood cell development. The Interferon Regulatory Factor 4 (IRF4) gene encodes a transcription factor important for key developmental stages of hematopoiesis, with known oncogenic implications in multiple myeloma, adult leukemias and lymphomas. Very few studies have reported an association of IRF4 with childhood malignancy, whereas high transcript levels have been observed in the more mature immunophenotype of ALL. Our aim was to investigate the expression levels of IRF4 in the diagnostic samples of pediatric leukemias and compare them to those of healthy controls, in order to determine aberrant gene expression and whether it extends to leukemic subtypes other than the relatively mature ALL subpopulation. Quantitative real-time RT-PCR methodology was used to investigate IRF4 expression in 58 children with acute leukemias, 4 leukemic cell lines and 20 healthy children. We show that aberrant IRF4 gene expression is implicated in a variety of leukemic subtypes; higher transcript levels appear in the more immature B-common ALL subtype and in T-cell than in B-cell leukemias, with the highest expression levels appearing in the AML group. Interestingly, we show that childhood leukemia, irrespective of subtype or cell maturation stage, is characterised by a minimum of approximately twice the amount of IRF4 gene expression encountered in healthy children. A statistically significant correlation also appeared to exist between high IRF4 expression and relapse. Our results show that ectopic expression of IRF4 follows the reverse expression pattern of what is encountered in normal B-cell development and that there might be a dose-dependency of childhood leukemia for aberrantly expressed IRF4, a characteristic that could be explored therapeutically. It is also suggested that high IRF4 expression might be used as an additional prognostic marker of relapse at diagnosis.
authors: Pediatric Hematology/Oncology Unit, First Department of Pediatrics, University of Athens, Aghia Sofia Children's Hospital, Athens, Greece. madamaki@med.uoa.gr
authors: Maria
authors: M
authors: Adamaki
authors: George I
authors: GI
authors: Lambrou
authors: Anastasia
authors: A
authors: Athanasiadou
authors: Marianna
authors: M
authors: Tzanoudaki
authors: Spiros
authors: S
authors: Vlahopoulos
authors: Maria
authors: M
authors: Moschovi
mesh_terms: D000293:Adolescent; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D002648:Child; D002675:Child, Preschool; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D050835:Interferon Regulatory Factors / Q000235:genetics*; D015448:Leukemia, B-Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D015458:Leukemia, T-Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D012008:Recurrence; D016019:Survival Analysis; D000099218:Interferon Regulatory Factor-4
chemical_list: D050835:Interferon Regulatory Factors; D000099218:Interferon Regulatory Factor-4
references: Leukemia. 1999 Nov;13(11):1812-6
references: 10557056
references: Blood. 2001 Jun 1;97(11):3648-50
references: 11369663
references: Mol Cell Biol. 1996 Apr;16(4):1283-94
references: 8657101
references: Blood. 2008 Nov 1;112(9):3798-806
references: 18713947
references: Nature. 2008 Jul 10;454(7201):226-31
references: 18568025
references: Cancer Cell. 2002 Mar;1(2):133-43
references: 12086872
references: J Immunol. 2005 Nov 15;175(10):6570-9
references: 16272311
references: Science. 1997 Jan 24;275(5299):540-3
references: 8999800
references: Leukemia. 2010 Apr;24(4):877-81
references: 20090783
references: Leuk Lymphoma. 2008 Feb;49(2):273-80
references: 18231914
references: Semin Hematol. 2003 Oct;40(4):268-73
references: 14582077
references: Int J Clin Exp Pathol. 2008 Mar 30;1(6):461-74
references: 18787682
references: J Exp Med. 2004 Jul 19;200(2):247-53
references: 15249594
references: J Interferon Cytokine Res. 2005 Dec;25(12):770-9
references: 16375605
references: Blood. 2002 Dec 15;100(13):4671-5
references: 12393648
references: Cancer Res. 2003 Aug 15;63(16):4882-7
references: 12941810
references: Leukemia. 2008 Jan;22(1):66-77
references: 17851551
references: Lancet Oncol. 2010 May;11(5):429-38
references: 20409752
references: Best Pract Res Clin Haematol. 2012 Mar;25(1):13-28
references: 22409820
references: Genes Dev. 2003 Sep 15;17(18):2298-307
references: 12952893
references: Cancer Cell. 2008 Jul 8;14(1):47-58
references: 18598943
references: Blood. 2009 Apr 16;113(16):3754-64
references: 19047678
references: Jpn J Cancer Res. 2002 Jun;93(6):685-94
references: 12079517
references: Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):503-10
references: 17702640
references: Blood. 2000 Mar 15;95(6):2084-92
references: 10706878
references: J Interferon Cytokine Res. 2002 Jan;22(1):111-20
references: 11846982
references: Annu Rev Immunol. 2004;22:55-79
references: 15032574
references: Blood. 2010 Jun 17;115(24):5061-8
references: 20393130
references: Leuk Res. 2009 Dec;33(12):1684-95
references: 19450877
references: Nature. 2006 Aug 17;442(7104):818-22
references: 16862118
references: Immunol Rev. 2012 May;247(1):73-92
references: 22500833
references: Trends Immunol. 2008 Oct;29(10):487-92
references: 18775669
references: Blood. 1998 Jan 1;91(1):22-9
references: 9414265
references: Cancer Causes Control. 2013 Jun;24(6):1111-8
references: 23529470
references: Clin Cancer Res. 2009 May 1;15(9):2954-61
references: 19383829
references: Genes Dev. 1996 Sep 15;10(18):2335-47
references: 8824592
references: Immunity. 2006 Aug;25(2):225-36
references: 16919487
references: Biochim Biophys Acta. 2010 Feb;1802(2):292-300
references: 19897031
references: J Invest Dermatol. 2010 Mar;130(3):816-25
references: 19812605
references: Nat Immunol. 2006 Jul;7(7):773-82
references: 16767092
references: J Exp Med. 2006 Jan 23;203(1):63-72
references: 16380510
references: Haematologica. 2006 Apr;91(4):467-74
references: 16585013
references: J Exp Med. 2000 Apr 17;191(8):1281-92
references: 10770796
references: Cancer Cell. 2007 Sep;12(3):280-92
references: 17785208
references: PLoS One. 2011;6(10):e25812
references: 22003407
references: Blood. 1993 Jul 15;82(2):343-62
references: 8329694
references: J Exp Med. 1999 Dec 20;190(12):1837-48
references: 10601358
references: N Engl J Med. 2004 Apr 8;350(15):1535-48
references: 15071128
references: J Clin Oncol. 2000 Oct 1;18(19):3331-8
references: 11013272
references: Blood. 1997 Apr 1;89(7):2488-93
references: 9116293